Dysmenorrhea Treatment Market Size by Type, Subtype, Distribution Channel, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2030
Overview
The Dysmenorrhea Treatment Market size was valued at USD 5.84 billion in 2023 and the total Dysmenorrhea Treatment Market revenue is expected to grow at a CAGR of 8.4 % from 2024 to 2030, reaching nearly USD 10.27 billion.
Dysmenorrhea is the medical term for painful menstrual periods that are caused due to uterine contractions. Generally, the pain is in the pelvis or lower abdomen and symptoms such as diarrhoea, fatigue and mood swings typically last less than three days during menstrual periods. Pain relief medication such as paracetamol, and regular exercise, release natural chemicals which relieve pain are the treatment options for period pain. The report includes a detailed analysis of Dysmenorrhea Treatment market potential, historical data, current trends and future trends and upcoming opportunities. The primary and secondary data collection methods to collect data for the qualitative and quantitative analysis of the Dysmenorrhea Treatment industry.
To know about the Research Methodology :- Request Free Sample Report
Dysmenorrhea Treatment Market Dynamics
Increasing prevalence of Dysmenorrhea to boosts the market growth:
Genetic factors, stress, depression, and anxiety are the main factors associated with Dysmenorrhea and menstrual disorders. The women’s age parity and use of oral contraceptives have been inversely related to Dysmenorrhea. The factors such as cigarette smoking, pelvic infections, eating fast food, a low body mass index (BMI), diet, a history of sexual assault, and obesity are also causing the problem of Dysmenorrhea. The unfavourable effects of Dysmenorrhea have been caused by an individual’s psychological status, and health-related quality of life (HRQoL) might be disrupted among adolescent women. Around 40 percent, of the menstrual period pain is assisted by premenstrual symptoms including bloating, tender breasts, lack of concentration mood swings and tiredness. All these factors help to increase the prevalence of Dysmenorrhea and influence Dysmenorrhea Treatment Market growth.
Increasing research and development activities about Dysmenorrhea to fuel the market:
The development of the Dysmenorrhea Symptom Interference scale has been used to measure the scales of the Dysmenorrhea Symptom interference with physical, mental and social activities. These measures are divided into generic pain measures and tools designed to measure premenstrual symptoms and varying degrees of exhaustiveness of symptoms measured, relevance to PD, multidimensionality and psychometric soundness. On the other hand, development of the innovative drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytic have been tested, exhibiting the large potential for research for the development of effective combinations and introducing the new combination of drugs for Dysmenorrhea. As a result, research and development activities boost the Dysmenorrhea Treatment Market growth.
Dysmenorrhea Treatment Market Opportunity:
The newly launched products for treating the pain associated with primary and secondary Dysmenorrhea such as Nonsteroidal anti-inflammatory drugs (NSAIDs), oral contraceptive pills (OCPs) and progestin-only pills (POPs). These products have been helpful in reducing menstrual pains and managing moderate to severe pain regards with endometriosis. In addition, the increase in awareness about reproductive health resulted to rising the new start-ups that offer period care such as menstrual cups and menstrual sterilizers which are affordable and electrical. For instance, The start-up was founded in 2020, by Vaishnavi Raju. The Hyderabad-based focuses on women’s healthcare by initiating friendly conservation around sexual intimacy, menopause, fertility pregnancy and menstruation driving the Dysmenorrhea Treatment Market growth.
Dysmenorrhea Treatment Market Restraints:
Lack of public awareness, high cost of care and insufficient reimbursement policies restrain the Dysmenorrhea Treatment Market expansion. The side effects and issues of the Dysmenorrhea Treatment such as high morbidity of menstrual cramps due to inadequacy of the testaments also negatively affect the market potential. The traditional family values and long-term treatment of Dysmenorrhea Treatment hamper the growth of the Dysmenorrhea Treatment Market.
Dysmenorrhea Treatment Market Segment Analysis:
Based on Type, the Dysmenorrhea Treatment Market is categorized into Primary Dysmenorrhea and Secondary Dysmenorrhea. Primary Dysmenorrhea dominated the market and is expected to dominate the market over the forecast period. Primary Dysmenorrhea is more effective rather than Secondary Dysmenorrhea. Due to primary Dysmenorrhea, Aleve's single maximum non-prescription dose offers more pain relief lasting 12 to 72 hours than acetaminophen for menstrual cramps. Also, In Primary Dysmenorrhea, painful menstrual cramps occur one or two days before menstrual bleeding. It is happening in the lower abdomen, back, or thigh and is very painful for menstrual cramps. As a result, Primary Dysmenorrhea boosts Dysmenorrhea Treatment Market growth.
Based on Treatment, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapy, Pain Reliever, Surgery and Others. In 2022, Nonsteroidal anti-inflammatory drugs (NSAIDs) held the largest Dysmenorrhea Treatment Market share and are expected to grow at a significant CAGR for the market. Nonsteroidal anti-inflammatory drugs (NSAIDs), a well-established therapy and first-line treatment for Dysmenorrhea and relieve primary Dysmenorrhea, suppress the endometrial production of endometrial prostaglandins, encourage cramps and restore better and normal uterine activity. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the action of cyclooxygenase (COX), which enzymes responsible for the formation of prostaglandins. All the factors contributing to the growth of the Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment.
Regional Analysis of Dysmenorrhea Treatment Market:
North America dominated the Dysmenorrhea Treatment Market and is expected to continue its dominance during the forecast period. The increasing prevalence and incidence of Dysmenorrhea, the presence of the major product manufacturers, growing awareness regarding the disease among women and the well-established healthcare sector are the influencing factors for the regional market growth. The United States is expected to have significant growth for Dysmenorrhea Treatment and drive the regional market growth. The presence of the key market players, approval of new drugs by the FDA, increasing research and development activities and increasing healthcare expenditure are the influencing factors for the growth of the Dysmenorrhea Treatment Market.
The increasing launching of new products for treating pain which is associated with primary as well as secondary dysmenorrhea and the consumption of the pharmaceuticals are also growth contributors to the United States market. Europe is expected to grow at a significant CAGR for the Dysmenorrhea Treatment Market during the forecast period. The increasing prevalence of menstrual health issues and Dysmenorrhea, the growing number of research and development activities, increasing investment in the healthcare sector, and increasing demand for effective treatments for Dysmenorrhea, expansion of the healthcare infrastructure, growing initiatives by the government and pharmaceutical companies are the boosting factors for the regional Dysmenorrhea Treatment Market growth.
Competitive Landscape Analysis of Dysmenorrhea Treatment Market:
Some of the Dysmenorrhea Treatment Market key players are Novartis AG,Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, and Focus Consumer Healthcare. These key players have adopted strategies including pricing, investments, expansion of the product portfolio, mergers and acquisitions, collaboration, agreements and geographical expansion for the enhancement of the Dysmenorrhea Treatment industry. The companies have been developing and launches of new drugs and creating awareness about the prevalence dysmenorrhea of related to the treatment of Dysmenorrhea. For example, Novartis AG The company recommended initial daily dose is 100 to 150 mg. In milder cases, 75 to 100 mg daily is usually sufficient. Generally, the total daily dose should be divided into 2 or 3 separate doses, as applicable. In primary dysmenorrhea, the daily dose should be individually adjusted and is generally 50 to 150 mg. An initial dose of 50mg is usually sufficient. Treatment should be started on the appearance of the first symptoms and, depending on the symptomatology continued for a few days. Clinical studies have also revealed that in primary dysmenorrhea the active substance is capable of relieving the pain and reducing the extent of bleeding.
Dysmenorrhea Treatment Market Scope: Inquire before buying
| Global Dysmenorrhea Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | US $ 5.84 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 8.4% | Market Size in 2030: | US $ 10.27 Bn. |
| Segments Covered: | by Type | Primary Dysmenorrhea Secondary Dysmenorrhea |
|
| by Subtype | Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Harmonal Therapy Surgery |
||
| by Distribution Channel | Hospital Pharmacies Drug Stores and Retail Pharmacies Online Providers |
||
Dysmenorrhea Treatment Market Key Players:
North America
1. Pfizer Inc. (United States)
2. Johnson & Johnson (United States)
3. AbbVie Inc. (United States)
4. Bayer AG (United States)
5. Merck & Co., Inc. (United States)
6. Allergan plc (United States)
7. Sanofi (United States)
8. AstraZeneca (United Kingdom)
9. Eli Lilly and Company (United States)
10. GlaxoSmithKline plc (United Kingdom)
11. Perrigo Company plc (Ireland)
12. Roche Laboratories (United States)
Europe
13. Bayer AG (Germany)
14. Novartis International AG (Switzerland)
15. AstraZeneca (United Kingdom)
16. GlaxoSmithKline plc (United Kingdom)
17. Ferring Pharmaceuticals (Switzerland)
Asia Pacific
18. Takeda Pharmaceutical Company Limited (Japan)
19. Sun Pharmaceutical Industries Ltd (India)
20. Daiichi Sankyo Company, Limited (Japan)
21. China Resources Pharmaceutical Group Limited (China)
22. Cipla Limited (India)
FAQs:
1. What are the growth drivers for the Market?
Ans. Increasing prevalence of Dysmenorrhea to boosts the market growth is the major driver for the Market.
2. What is the major Opportunity for the Market growth?
Ans. Increasing research and development activities about Dysmenorrhea to fuel the market.
3. Which country is expected to lead the Market during the forecast period?
Ans. North America is expected to lead the Dysmenorrhea Treatment Market during the forecast period.
4. What is the projected market size and growth rate of the Dysmenorrhea Treatment Market?
Ans. The Dysmenorrhea Treatment Market size was valued at USD 5.84 billion in 2023 and the total Dysmenorrhea Treatment Market revenue is expected to grow at a CAGR of 8.4 % from 2024 to 2030, reaching nearly USD 10.27 billion.
5. What segments are covered in the Dysmenorrhea Treatment Market report?
Ans. The segments covered in the Dysmenorrhea Treatment Market report are by Type, Treatment, Distribution Channel, and Region.
